FBLG News & Events

FibroBiologics announced the pricing of a best efforts public offering of an aggregate of 2,272,728 shares of its common stock and warrants to purchase up to 2,272,728 shares of common stock, at a combined public offering price of $1.32 per share and accompanying Warrant. The Warrants will have an exercise price of $1.32 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants and will expire on the five-year anniversary of the date of Stockholder Approval. The closing of the offering is expected to occur on or about April 2, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

FibroBiologics announced the completion of manufacturing of the first batch of FibroBiologics' proprietary CYWC628 drug product that will support upcoming first-in-human clinical trials. Manufactured in accordance with the FDA's Good Manufacturing Practices, the drug product will be released after it successfully passes all required safety and quality testing. "CYWC628 is not only the first fibroblast-based spheroid therapeutic candidate, its manufacture also represents the first large-scale CGMP manufacturing of a spheroid product for therapeutic use," said Pete O'Heeron, Founder and CEO of FibroBiologics. "These achievements by our scientific team allow us to move forward with our planned Phase 1/2 clinical trial utilizing CYWC628 in DFU patients in the first half of 2026."